Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities

References

• Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii–iv.
   Web of Science ®Google Scholar
• Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ. 2017;20(4):345–352.
   PubMed Web of Science ®Google Scholar
• Kurimoto M, Kimura M, Usami E, et al. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Mol Clin Oncol. 2017;7(1):125–130.
   PubMed Web of Science ®Google Scholar
• Rascati KL. Essentials of pharmacoeconomics. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2011.
   Google Scholar
• Bootman JL. Principles of pharmacoeconomics. Cincinnati, OH: H. Whitney Books; 1999.
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12(4):409–418.
   PubMed Web of Science ®Google Scholar
• Purchasing power parities – frequently asked questions (faqs) [Internet]. OECD; 2021 [cited 2021 Sep 19]. Available from: https://www.oecd.org/sdd/prices-ppp/purchasingpowerparities-frequentlyaskedquestionsfaqs.htm.
   Google Scholar
• PPP calculation and estimation [Internet]. World Bank; 2021 [cited 2021 Sep 19]. Available from: https://www.worldbank.org/en/programs/icp/brief/methodology-calculation.
   Google Scholar
• Eurostat-OECD methodological manual on purchasing power parities (2012 edition) [Internet]. OECDiLibrary. Paris: OECD Publishing; 2012. [cited 2021 Sep 19]. Available from: https://www.oecd-ilibrary.org/economics/eurostat-oecd-methodological-manual-on-purchasing-power-parities_9789264189232-en.
   Google Scholar
• Price relative [Internet]. OECD glossary of statistical terms. Organisation for Economic Co-operation and Development; 2007 [cited 2021 Sep 19]. Available from: https://stats.oecd.org/glossary/detail.asp?ID=2111.
   Google Scholar
• OECD health statistics 2021 [Internet]. OECD; 2021 [cited 2021 Sep 19]. Available from: https://www.oecd.org/els/health-systems/health-data.htm.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). Seer cancer statistics review, 1975–2018 [Internet]. SEER [cited 2021 Sep 19]. Available from: https://seer.cancer.gov/csr/1975_2018/.
   Google Scholar
• Conroy T, Bachet JB, Ayav A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10–22.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Groupe tumeurs digestives of unicancer; PRODIGE intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Saif MW. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer. JOP. 2013;14(6):686–688.
   Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Coyle D, Ko YJ, Coyle K, et al. Cost-Effectiveness analysis of systemic therapies in advanced pancreatic cancer in the Canadian health care system. Value Health. 2017;20(4):586–592.
   PubMed Web of Science ®Google Scholar
• World development indicators: The World Bank; 2021 [cited 2021 Sep 19]. Available from: http://wdi.worldbank.org/table/4.16.
   Google Scholar
• Carrato A, García P, López R, et al. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):579–589.
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Papakostas P, Pentheroudakis G, et al. Economic evaluation of NAB-paclitaxel plus gemcitabine versus gemcitabine alone for the management of metastatic pancreatic cancer in Greece. Value Health. 2014;17(7):A632.
   PubMed Web of Science ®Google Scholar
• Gharaibeh M, McBride A, Bootman JL, et al. Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer. 2015;112(8):1301–1305.
   PubMed Web of Science ®Google Scholar
• Gharaibeh M, McBride A, Alberts DS, et al. Economic evaluation for the UK of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics. 2018;36(11):1333–1343.
   PubMed Web of Science ®Google Scholar
• Gharaibeh M, McBride A, Alberts DS, et al. Economic evaluation for USA of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics. 2018;36(10):1273–1284.
   PubMed Web of Science ®Google Scholar
• Lazzaro C, Barone C, Caprioni F, et al. An italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):435–446.
   PubMed Web of Science ®Google Scholar
• Stainthorpe A, Greenhalgh J, Bagust A, et al. Paclitaxel as Albumin-Bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(10):1153–1163.
   PubMed Web of Science ®Google Scholar
• Stetka R, Ondrusova M, Psenkova M, et al. A Cost-Utility analysis of Nab-Paclitaxel (abraxane) plus gemcitabine in metastatic pancreatic cancer in Slovak Republic. Value in Health. 2015;18(7):A464.
   Web of Science ®Google Scholar